The Presence of PAI-1 4G/5G and ACE DD Genotypes Increases the Risk of Early-Stage AVF Thrombosis in Hemodialysis Patients

REFERENCES

• Smits J, van der Linden J, Blankestijn PJ, Rabelink TJ. Coagulation and hemodialysis access thrombosis. Nephrol Dial Transplant. 2000;15:1755–1760.
   PubMed Web of Science ®Google Scholar
• US Renal Data System. Excerpts from the USRDS 2003 Annual Data Report: Atlas of end-stage renal disease in the United States. Am J Kidney Dis. 2003;42:S1–S230.
   Google Scholar
• Feldman HI, Kobrin S, Wasserstein A. Hemodialysis vascular access morbidity. J Am Soc Nephrol. 1996;7:523–535.
   PubMed Web of Science ®Google Scholar
• Schwab SJ. Vascular access for hemodialysis. Kidney Int. 1999;55:2078–2090.
   PubMed Web of Science ®Google Scholar
• LeSae CJ, Merrick HW, Smith MR. Thrombotic complications resulting from hypercoagulable states in chronic hemodialysis vascular access. Am Coll Surg. 1999;189:73–81.
   Google Scholar
• Weiss MF, Scivittaro V, Anderson JM. Oxidative stress and increased expression of growth factors in lesions of failed hemodialysis access. Am J Kidney Dis. 2001;37:970–980.
   PubMed Web of Science ®Google Scholar
• Daemen MJ, Lombardi DM, Bosman FT, Schwartz SM. Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall. Circ Res. 1991;68:450–456.
   PubMed Web of Science ®Google Scholar
• Tiret L, Rigat B, Visvikis S, Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels. Am J Hum Genet. 1992;51:197–205.
   PubMed Web of Science ®Google Scholar
• Wiwanitkit V. Angiotensin-converting enzyme gene polymorphism: I and D alleles from some different countries. Clin Appl Thromb Hemost. 2004;10(2):179–182.
   Google Scholar
• Kohler HP, Grant PJ. Mechanisms of disease: Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med. 2000;342:1801–1972.
   Google Scholar
• Eriksson P, Kalling B, van't Hooft FM, Allele-specific increase in basal transcription of the plasminogen activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA. 1995;92:1851–1855.
   PubMed Web of Science ®Google Scholar
• Mansfield MW, Stikland MH, Grant PJ. Plasminogen activator inhibitor-1 (PAI-1) promoter polymorphism and coronary artery disease in non-insulin dependent diabetes. Thromb Hemost. 1995;74:1032–1034.
   PubMed Web of Science ®Google Scholar
• Ikegaya N, Yamamoto T, Takeshita A, Elevated erythropoietin receptor and transforming growth factor-1 expression in stenotic arteriovenous fistulae used for hemodialysis. J Am Soc Nephrol. 2000;11:928–935.
   Google Scholar
• Aznar J, Estelles A, Tormo G, Plasminogen activator inhibitor activity and other fibrinolytic variables in patients with coronary artery disease. Br Heart J. 1988;59:535–541.
   PubMedGoogle Scholar
• Cambien F, Poirier O, Lecerf L, Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature. 1992;359:641–644.
   PubMed Web of Science ®Google Scholar
• Kim DK, Kim JW, Kim S, Polymorphism of angiotensin converting enzyme gene is associated with circulating levels of plasminogen activator inhibitor-1. Arterioscler Thromb Vasc Biol. 1997;17:3242–3247.
   PubMed Web of Science ®Google Scholar
• Van der Sman-de Beer F, Verhagen C, Rombach SM, ACE I/D polymorphism is associated with mortality in a cohort study of patients starting with dialysis. Kidney Int. 2005;68:2237–2243.
   Google Scholar
• So WY, Ma RC, Ozaki R, Angiotensin-converting enzyme (ACE) inhibition in type 2, diabetic patients: Interaction with ACE insertion/deletion polymorphism. Kidney Int. 2006;69:1438–1443.
   PubMedGoogle Scholar
• Ishimitsu T, Hosoya K, Matsuoka H. The deletion allele of angiotensin-converting enzyme gene polymorphism as a cardiovascular risk factor in patients undergoing long-term hemodialysis. Ann Intern Med. 2000;133:924.
   Google Scholar
• Paulson WD. Prediction of hemodialysis synthetic graft thrombosis: Can we identify factors that impair validity of the dysfunction hypothesis? Am J Kidney Dis. 2000;35:973–975.
   Google Scholar
• Philipp CS, Dilley A, Saidi P, Deletion polymorphism in the angiotensin-converting enzyme gene as a thrombophilic risk factor after hip arthroplasty. Thromb Hemost. 1998;80:869–873.
   Google Scholar
• Koppel H, Renner W, Gugl A, The angiotensin-converting enzyme insertion/deletion polymorphism is not related to venous thrombosis. Thromb Hemost. 2004;91:76–79.
   Google Scholar
• Dilley A, Austin H, Hooper WC, Relation of three genetic traits to venous thrombosis in an African-American population. Am J Epidemiol. 1998;147:30–35.
   Google Scholar
• Gonzales Ordonez AJ, Fernandez Carreira JM, Medina Rodriguez JM, Risk of venous thromboembolism associated with the insertion/deletion polymorphism in the angiotensin-converting enzyme gene. Blood Coagul Fibrinolysis. 2000;11(5):485–490.
   Google Scholar
• Makris TK, Stavroulakis GA, Dafni UG, ACE/DD genotype is associated with hemostasis balance disturbances reflecting hypercoagulability and endothelial dysfunction in patients with untreated hypertension. Am Heart J. 2000;140:760–765.
   PubMed Web of Science ®Google Scholar
• Jackson A, Brown K, Langdown J, Luddington R, Baglin T. Effect of the angiotensin-converting enzyme gene deletion polymorphism on the risk of venous thromboembolism. Br J Hematol. 2000;111:562–564.
   PubMedGoogle Scholar
• Isbir CS, Akgun S, Yilmaz H, Is there a role of angiotensin-converting enzyme gene polymorphism in the failure of arteriovenous femoral shunts for hemodialysis? Ann Vasc Surg. 2001;15:443–446.
   PubMed Web of Science ®Google Scholar
• Baek SH, Kye YH, Ahn SH. Role of ACE gene polymorphism on failure of arteriovenous fistula for maintenance of hemodialysis. Korean J Nephrol. 2003;22(6):664–670.
   Google Scholar
• Gradzki R, Dhingra RK, Port FK, Roys E, Weitzel WF, Messana JM. Use of ACE inhibitors is associated with prolonged survival of arteriovenous grafts. Am J Kidney Dis. 2001;38:1240–1244.
   Google Scholar
• Paulson WD, Ram SJ, Faiyaz R, Caldito GC, Atray NK. Association between blood pressure, ultrafiltration, and hemodialysis graft thrombosis: A multivariable logistic regression analysis. Am J Kidney Dis. 2002;40:769–776.
   Google Scholar
• Saran R, Dykstra DM, Wolfe RA, Gillespie B, Held PJ, Young EW. Association between vascular access failure and the use of specific drugs: The Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2002;40:1255–1263.
   PubMed Web of Science ®Google Scholar
• Heine GH, Ulrich C, Kohler H, Girndt M. Is AV fistula patency associated with angiotensin-converting enzyme (ACE) polymorphism and ACE inhibitor intake? Am J Nephrol. 2004;24:461–468.
   Google Scholar
• Brophy DF, Bukaveckas BL, Ferreira-Gonzalez A, Archer KJ, Martin EJ, Gehr TW. A pilot study of genetic polymorphism and hemodialysis vascular access thrombosis. Hemodial Int. 2009;13:19–26.
   Google Scholar
• Moon JY, Jeong KH, Paik SS, Arteriovenous fistula patency associated with angiotensin-converting enzyme I/D polymorphism and ACE inhibition or AT1 receptor blockade. Nephron Clin Pract. 2009;111:c110–c116.
   Google Scholar
• Tomura S, Nakamura Y, Doi M, Fibrinogen, coagulation factor VII, tissue plasminogen activator inhibitor-1, and lipid as cardiovascular risk factors in chronic hemodialysis and continuous ambulatory peritoneal dialysis patients. Am J Kidney Dis. 1996;27(6):848–854.
   PubMed Web of Science ®Google Scholar
• Stegnar M, Uhrin P, Peternel P, The 4G/5G sequence polymorphism in the promoter of plasminogen activator inhibitor-1 (PAI-1) gene: Relationship to plasma PAI-1 level in venous thromboembolism. Thromb Hemost. 1998;79(5):975–979.
   Google Scholar
• Yılmaz E, Akar E, Akar N. Effect of plasminogen activator inhibitor-1 4G/5G polymorphism in Turkish deep vein thromboembolic patients with and without prothrombin 20210 G-A. Turk J Hematol. 2004;21(2):83–86.
   Google Scholar
• Pfeffer MA, Braunwald E, Moye LA, Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 1992;327:669–677.
   PubMed Web of Science ®Google Scholar
• Akar N, Yılmaz E, Akar E, Effect of plasminogen activator inhibitor-1 4G/5G polymorphism in Turkish deep vein thrombotic patients with and without FV 1691 G-A. Thromb Res. 2000;97:227–230.
   Google Scholar
• Lazo-Langer A, Knoll AG, Wells SP, Carson N, Rodger AM. The risk of dialysis access thrombosis is related to the transforming growth factor-beta 1 production haplotype and is modified by polymorphism in the plasminogen activator inhibitor-type 1 gene. Blood. 2006;108:4052–4058.
   Google Scholar
• Fukasawa M, Matsushita K, Kamiyama M, The methylenetetrahydrofolate reductase C677T point mutation is a risk factor for vascular access thrombosis in hemodialysis patients. Am J Kidney Dis. 2003;41:637–642.
   PubMed Web of Science ®Google Scholar
• Girndt M, Heine GH, Ulrich C, Köhler H, DialGene Consortium. Gene polymorphism association studies in dialysis: Vascular access. Semin Dial. 2007;2(1):63–67.
   Google Scholar
• Bremer C, Schaefer RM. Heterozygosity for factor V Leiden in a hemodialysis patient with recurrent shunt thrombosis. Nephrol Dial Transplant. 1997;12:1775–1776.
   Google Scholar
• Atac B, Yakupoglu U, Ozbek N, Ozdemir FN, Bilgin N. Role of genetic mutations in vascular access thrombosis among hemodialysis patients waiting for renal transplantation. Transplant Proc. 2002;34:2030–2032.
   PubMed Web of Science ®Google Scholar
• Kim RJ, Becker RC. Association between factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations and events of the arterial circulatory system: A meta-analysis of published studies. Am Heart J. 2003;146:948–957.
   PubMed Web of Science ®Google Scholar
• Akman B, Afsar B, Ataç FB, Predictors of vascular access thrombosis among patients on the cadaveric renal transplantation waiting list. Transplant Proc. 2006;38:413–415.
   Google Scholar
• Knoll AG, Wells SP, Young D, Thrombophilia and the risk for hemodialysis vascular access thrombosis. J Am Soc Nephrol. 2005;16:1108–1114.
   PubMed Web of Science ®Google Scholar